The inhibition of CBR1 activity can enhance the effectiveness and decrease the cardiotoxicity of the anticancer drug anthracycline daunorubicin (DNR) in hepatocellular carcinoma (Huang et al., 2010). The gene discussed is CBR1; the disease is hepatocellular carcinoma.